UNITY Biotechnology Announces Extension of Series B Financing Bringing Total Round to $151 MillionAppoints Biotech Industry Veteran Graham Cooper to Board of Directors SAN FRANCISCO, August 17, 2017-- UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of an additional $35 million in Series B financing. This second close of the Series B, in addition to the initial close in fall of 2016, brings the total amount of this financing to $151 million.